×

RNAi modulation of MLL-AF4 and uses thereof

  • US 8,034,793 B2
  • Filed: 02/04/2010
  • Issued: 10/11/2011
  • Est. Priority Date: 12/14/2004
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a disorder associated with MLL-AF4 fusion expression comprising administering to a subject having or at risk for developing said disorder a composition comprising an iRNA agent, wherein said iRNA agent comprises a sense strand and an antisense strand and the antisense strand consists of SEQ ID NO:

  • 15.

View all claims
  • 4 Assignments
Timeline View
Assignment View
    ×
    ×